GHK-Cu: The Copper Peptide With 50 Years of Research and Still No Approval Anywhere
Complete Guide to Peptides Editorial Team
This article is provided for general informational purposes only and is not medical advice. Speak to a qualified healthcare professional before making any decisions about peptide use.
Copper peptide GHK-Cu was first identified in human plasma back in the 1970s, by biochemist Loren Pickart, who noticed that older plasma samples were noticeably worse at stimulating tissue growth in liver cell cultures than younger ones. The compound responsible turned out to be a tiny copper-binding tripeptide, glycine, histidine, lysine, and five decades later it’s still one of the most heavily studied peptides in dermatology and regenerative research. It’s also still not an approved medicine anywhere in the world. That combination, decades of accumulated science and zero regulatory approval, makes GHK-Cu a genuinely interesting case study, and one that’s about to get more regulatory attention on both sides of the Atlantic.
What the actual research shows
GHK-Cu occurs naturally in the body, and levels decline steadily with age, from roughly 200 ng/mL in plasma at age 20 down to around 80 ng/mL by 60, a drop that tracks fairly closely with the slowdown in wound healing and skin regeneration most people experience as they get older. That correlation is a big part of why the compound has attracted sustained research interest: it looks like a naturally occurring signal that fades exactly when regenerative capacity does.
The skin and wound-healing evidence base is genuinely more substantial than most peptides in this space. A 2024 randomised controlled trial of 60 women aged 40 to 65 found a topical 0.1% GHK-Cu cream, applied twice daily for 12 weeks, produced a 31% reduction in wrinkles and a 28% improvement in skin elasticity compared to placebo, with collagen density up 15.6% on ultrasound. An earlier double-blind study combining GHK-Cu with hyaluronic acid found similar improvements in fine lines and hydration. More significantly, a 2025 meta-analysis pooling seven randomised controlled trials found a statistically significant effect on wrinkle reduction across the combined data, though the researchers flagged real limitations too: small sample sizes in the underlying trials, and industry funding behind a substantial share of them, both of which are reasons for measured rather than uncritical confidence in the result.
Beyond skin, the mechanistic research is what really sets GHK-Cu apart. A Broad Institute analysis using gene expression mapping found that GHK, at very low concentrations, measurably affects expression of more than 1,000 human genes, spanning extracellular matrix remodelling, inflammation control and cellular repair pathways. That’s an unusually broad genomic footprint for a three-amino-acid compound, and it’s part of why research interest in GHK-Cu extends well past skin, into general wound healing, connective tissue and even early neurological research.
Why none of that has translated into approval
Here’s the pattern that should sound familiar if you’ve followed the BPC-157 story: strong mechanistic and preclinical research, a genuinely useful body of human trial data for the topical cosmetic use case specifically, and still nothing resembling FDA or MHRA drug approval. Topical GHK-Cu occupies a comparatively settled legal position, it can be lawfully included in cosmetic products in both the US and UK, provided it’s marketed on cosmetic rather than medical claims. Injectable and systemic GHK-Cu is a different story entirely. It was placed on the FDA’s Category 2 restricted list in 2023, the same “significant safety concerns” flag that applied to BPC-157 and TB-500 before their own recent review.
That’s now changing. FDA’s April 2026 Federal Register notice named GHK-Cu for a second Pharmacy Compounding Advisory Committee review, specifically covering non-injectable routes, expected to conclude before the end of February 2027. It’s one of five peptides queued for that second hearing, alongside Melanotan II, Cathelicidin (LL-37), Dihexa acetate and Mechano Growth Factor, the same batch we flagged in our timeline piece on the July vote. GHK-Cu’s stronger human evidence base, relative to something like MOTS-c or KPV, might make it one of the more straightforward recommendations to come out of that meeting, though that’s an educated read on the pattern rather than a certainty.
The UK angle: this isn’t just an American story
While the FDA process plays out, UK regulators have been dealing with a related but distinct problem. In April 2026, the MHRA opened an investigation into UK clinics after a Guardian investigation found several were advertising experimental peptide treatments, including BPC-157 and Cortexin, with specific claims about tissue repair, injury recovery and cognitive enhancement, despite labelling the products “research use only.” One clinic’s website described BPC-157 as aiding tissue repair and recovery from injuries, and Thymosin Alpha as boosting immune function, statements that cross directly into medicinal claims under UK law. An MHRA spokesperson was blunt about the legal position: if a clinic makes a medicinal claim about a peptide treatment, that treatment is legally a medicine, and needs to be regulated as one, regardless of what the label says.
The relevant legal framework in the UK is the Human Medicines Regulations 2012, and the distinction that matters is intent and claims, not just the compound itself. Research peptides sold genuinely for laboratory research, without medical or dosing claims attached, sit outside medicines regulation. The moment a seller or clinic starts describing specific health benefits, treatment protocols, or intended human outcomes, that framing brings the product back under medicines law, and that’s exactly the line the MHRA’s investigation is testing.
This matters for anyone in the UK following the GHK-Cu story specifically, because it’s precisely the kind of compound this enforcement pattern is aimed at: genuine underlying research, but a supply and marketing landscape that regularly overstates what that research actually supports for human use.
Where that leaves GHK-Cu right now
Nothing about GHK-Cu’s legal status has changed in either country. It’s not FDA-approved, and it holds no UK marketing authorisation as a medicine. Topical, cosmetically-marketed GHK-Cu products remain lawful in both markets under existing cosmetics regulation. Injectable and research-grade GHK-Cu remains in the same category as BPC-157 and its peers: available through the research peptide market, not through any prescription pathway, and now facing formal regulatory review on both sides of the Atlantic, FDA’s PCAC process concluding by February 2027, and increased MHRA scrutiny of how it’s marketed here in the UK.
Given both of those developments are live, sourcing from a supplier that actually documents what they sell, batch-specific testing, accurate labelling, no health claims, matters more than usual right now. Complete Peptides is who we’d point UK researchers toward for that.
We’ll update this page once the FDA’s February 2027 review concludes, or if the MHRA investigation produces any formal enforcement outcomes.
Sources: FDA, Federal Register notice on the second PCAC advisory review (April 2026); MHRA statements reported by The Guardian and the BBC (April 2026); published meta-analysis and randomised controlled trial data on topical GHK-Cu (2024-2025)
